Humana (HUM) Price Target Raised to $330.00 at Argus

Humana (NYSE:HUM) had its price target boosted by Argus from $270.00 to $330.00 in a report issued on Monday. Argus currently has a buy rating on the insurance provider’s stock.

Several other equities analysts have also issued reports on the stock. Zacks Investment Research raised shares of Humana from a hold rating to a buy rating and set a $316.00 price objective on the stock in a report on Friday. Piper Jaffray reaffirmed a buy rating and issued a $313.00 price target on shares of Humana in a report on Wednesday, April 4th. ValuEngine raised shares of Humana from a hold rating to a buy rating in a report on Monday, April 2nd. JPMorgan Chase lifted their price target on shares of Humana from $253.00 to $271.00 and gave the stock a neutral rating in a report on Monday, February 12th. Finally, Deutsche Bank lifted their price target on shares of Humana from $259.00 to $270.00 and gave the stock a hold rating in a report on Friday, February 9th. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Humana presently has a consensus rating of Buy and an average price target of $277.05.

How to Become a New Pot Stock Millionaire

Shares of NYSE HUM opened at $289.95 on Monday. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.48. The stock has a market capitalization of $39,600.76, a price-to-earnings ratio of 24.76, a PEG ratio of 1.55 and a beta of 0.97. Humana has a 1 year low of $210.01 and a 1 year high of $293.35.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.06. Humana had a net margin of 4.55% and a return on equity of 16.13%. The firm had revenue of $13.19 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same quarter in the previous year, the firm posted $2.34 earnings per share. The company’s revenue was up 2.4% on a year-over-year basis. sell-side analysts predict that Humana will post 13.86 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be given a dividend of $0.50 per share. The ex-dividend date is Wednesday, March 28th. This is an increase from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 dividend on an annualized basis and a yield of 0.69%. Humana’s payout ratio is currently 17.08%.

In related news, CEO Bruce D. Broussard sold 14,075 shares of the company’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $274.32, for a total transaction of $3,861,054.00. Following the completion of the transaction, the chief executive officer now owns 113,896 shares in the company, valued at approximately $31,243,950.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider M Todoroff Christopher sold 16,389 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total transaction of $4,480,260.93. Following the transaction, the insider now owns 13,447 shares of the company’s stock, valued at approximately $3,676,006.39. The disclosure for this sale can be found here. In the last quarter, insiders sold 31,660 shares of company stock valued at $8,668,218. Insiders own 0.60% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Daiwa SB Investments Ltd. grew its stake in Humana by 44.9% during the 4th quarter. Daiwa SB Investments Ltd. now owns 710 shares of the insurance provider’s stock valued at $176,000 after acquiring an additional 220 shares in the last quarter. HL Financial Services LLC grew its stake in Humana by 2.1% during the 4th quarter. HL Financial Services LLC now owns 11,205 shares of the insurance provider’s stock valued at $2,780,000 after acquiring an additional 230 shares in the last quarter. CIBC Asset Management Inc grew its stake in Humana by 1.5% during the 4th quarter. CIBC Asset Management Inc now owns 16,996 shares of the insurance provider’s stock valued at $4,216,000 after acquiring an additional 248 shares in the last quarter. YorkBridge Wealth Partners LLC grew its stake in Humana by 99.0% during the 4th quarter. YorkBridge Wealth Partners LLC now owns 597 shares of the insurance provider’s stock valued at $159,000 after acquiring an additional 297 shares in the last quarter. Finally, Chicago Equity Partners LLC grew its stake in Humana by 0.8% during the 4th quarter. Chicago Equity Partners LLC now owns 42,675 shares of the insurance provider’s stock valued at $10,586,000 after acquiring an additional 345 shares in the last quarter. Hedge funds and other institutional investors own 96.42% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Humana (HUM) Price Target Raised to $330.00 at Argus” was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://weekherald.com/2018/04/17/humana-hum-price-target-raised-to-330-00-at-argus.html.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply